Recent Research Analysts’ Ratings Changes for Aurora Cannabis (ACB)

A number of research firms have changed their ratings and price targets for Aurora Cannabis (NASDAQ: ACB):

• 8/26/2026 – Aurora Cannabis was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/11/2026 – Aurora Cannabis was downgraded by Weiss Ratings from “sell (d)” to “sell (e+)”.
• 8/8/2026 – Aurora Cannabis was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 8/7/2026 – Aurora Cannabis was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/5/2026 – Aurora Cannabis was upgraded by BMO Capital Markets to “hold”.

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.